Top of the morning to you, and a fine one, it is, thanks to clear skies and refreshingly cool temperatures enveloping the Pharmalot campus. Our short person has been deposited at the local schoolhouse for another day of learning and our mascot is quietly snoozing in his corner. All of which is to say that we can now fire up the coffee kettle, brew a cup of stimulation, and dig in for another busy day. No doubt, you may be equally busy. So to help you along, here are a few tidbits. Hope all goes well today. You deserve it.

The Food and Drug Administration announced that Denton Pharma and Appco Pharma are voluntarily recalling batches of ranitidine heartburn tablets and Mylan (MYL) is voluntarily recalling lots of nizatidine heartburn tablets in the U.S. due to traces of NDMA, a possible carcinogen. The agency has not found evidence the medicines, including Zantac, form NDMA in patient stomachs or small intestines, but has previously indicated some contain higher than acceptable levels and asked manufacturers to voluntarily withdraw those pills.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy